Summary

219.57 1.02(0.47%)01/15/2026
Johnson & Johnson (JNJ)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 Years
0.472.709.2916.6935.8536.9664.74


Last 730 data points are shown. To view all data, Upgrade to PRO plan!


Fundamental Ratings
CategoryRating
Main RatingA
Recommended RatingBuy
DCFBuy
ROEStrong Buy
ROAStrong Buy
Debt/EquityNeutral
P/ENeutral
P/BSell


Earnings
  • JNJ reported last earnings on 2025-10-14 after the market.
  • An EPS of $2.8 was observed compared to an estimated EPS of $2.76, resulting in a surprise value of $0.04.
  • A revenue of $23,993 million was observed compared to an estimated revenue of $23,755 million, resulting in a surprise value of $238 Million.


  • Trading Data
    Close219.57
    Open217.84
    High219.75
    Low215.91
    Volume6,197,444
    Change1.02
    Change %0.47
    Avg Volume (20 Days)9,414,506
    Volume/Avg Volume (20 Days) Ratio0.66
    52 Week Range137.68 - 207.72
    Price vs 52 Week High5.70%
    Price vs 52 Week Low59.47%
    Range0.00
    Gap Up/Down0.36
    Profitibility
    Market Capitalization (Mln)451,213
    Revenue per share37.9433
    Net Income per share10.3430
    Dividend Yield0.0234
    Dividend Share514.00%
    Valuations
    Enterprise Value0.00%
    PE Ratio21.2289
    PB Ratio0.0000
    PTB Ratio0.0000
    Liquidity
    Debt/Equity Ratio0.0000
    Net Debt/EBIDTA Ratio0.0000
    Current Ratio0.0000
    Enterprise Value and Cash Flow
    EV/Sales Ratio0.0000
    EV/EBIDTA Ratio0.0000
    EV/Free Cash Flow Ratio0.0000


    01/15 17:35 EST - gurufocus.com
    Market Today: TSMC beat, Goldman soars, Spotify hikes
    Stock News Verizon issues credits after outage: Verizon (VZ) said it resolved a nationwide wireless outage and will offer a $20 account credit to affected custo
    01/15 10:16 EST - zacks.com
    Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings, Beyond Revenue and EPS
    Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
    01/15 04:06 EST - defenseworld.net
    Citizens Financial Group Inc. RI Has $36.24 Million Holdings in Johnson & Johnson $JNJ
    Citizens Financial Group Inc. RI increased its position in shares of Johnson and Johnson (NYSE: JNJ) by 18.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 195,465 shares of the company's stock after...
    01/15 04:06 EST - defenseworld.net
    First Horizon Corp Takes $26.66 Million Position in Johnson & Johnson $JNJ
    First Horizon Corp bought a new position in shares of Johnson and Johnson (NYSE: JNJ) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund bought 143,770 shares of the company's stock, valued at approximately $26,658,000. Johnson and Johnson...
    01/14 16:30 EST - prnewswire.com
    TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
    TECVAYLI® alone reduced risk of disease progression or death by 71% in a high unmet need population MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson &...
    01/14 11:01 EST - zacks.com
    Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
    Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
    01/14 10:00 EST - zacks.com
    Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
    Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
    01/14 07:39 EST - gurufocus.com
    First Look: Alphabet $4T, Nvidia China OK, Boeing Tops Airbus
    Stock News Saks Global files Chapter 11: Saks Global (private) sought Chapter 11 protection, citing heavy debt from its 2024 Neiman Marcus deal and inventory st
    01/13 10:24 EST - feeds.benzinga.com
    Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
    Delaware's top court overturned part of a $1 billion damages award against Johnson and Johnson in the Auris Health merger, ordering a recalculation that could lower payouts.
    01/13 08:50 EST - zacks.com
    What's Powering J&J's MedTech Growth Ahead of Q4 Release?
    JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.
    01/13 08:09 EST - feeds.benzinga.com
    AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines
    AbbVie agrees to lower drug prices, invest $100 billion in the U.S., expand manufacturing, and secure tariff relief.
    01/13 08:00 EST - prnewswire.com
    Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
    New CAPLYTA ® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in adjunctive major depressive disorder (aMDD) to be presented SPRAVATO ® (esketamine) effects on anhedonia in treatment-resistant depression (TRD) – Phase 3 data post-hoc analyses to be presented...
    01/13 02:40 EST - seekingalpha.com
    Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
    Mar Vista's U.S. Quality strategy returned +0.20% net-of-fees in Q4 2025. The Russell 1000 Index and the S&P 500 Index returned +2.41% and +2.65%, respectively. Alphabet, Johnson & Johnson and Danaher Corp. were among the portfolio's top contributors for the quarter.
    01/12 18:45 EST - zacks.com
    Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know
    Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.
    01/12 14:06 EST - seekingalpha.com
    Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
    Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
    01/12 12:49 EST - 247wallst.com
    How Much Monthly Income Does a $2 Million Portfolio Produce at Age 60?
    At 60 years old with $2 million saved, you can safely say that you are in a good position that most people will never reach. At this point, the question in your mind should shift from whether you have enough to retire to how much income you can generate from a $2 million portfolio to... How Much...
    01/12 06:26 EST - defenseworld.net
    Invested Advisors Buys New Stake in Johnson & Johnson $JNJ
    Invested Advisors purchased a new stake in Johnson and Johnson (NYSE: JNJ) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 6,597 shares of the company's stock, valued at approximately $1,223,000. Johnson and Johnson makes up about...
    01/12 04:00 EST - defenseworld.net
    Birch Hill Investment Advisors LLC Sells 12,895 Shares of Johnson & Johnson $JNJ
    Birch Hill Investment Advisors LLC trimmed its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 8.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 138,455 shares of the company's stock after selling 12,895 shares...
    01/11 07:40 EST - forbes.com
    The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
    The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.

    Market News ×
    Loading news…